Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CFDA's Order On Chinese Pharmacopoeia Could Lead To Greater Testing Of Imported Medicines

This article was originally published in SRA

Executive Summary

Foreign medicinal products entering China could face greater testing at customs ports and encounter potential hurdles - especially with regard to products not included in the revised Chinese Pharmacopoeia (ChP) - following the China Food and Drug Administration's recent notice reinforcing the applicability of ChP to all imported drugs, say lawyers at Sidley Austin1,2.

Advertisement
Advertisement
UsernamePublicRestriction

Register